Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. Optimizing Antibody-Based Therapies for Alzheimer's Disease: From Clinical Limitations to Molecular Engineering Innovations 2026-06-04
  2. Immunotherapeutic Innovations in Alzheimer's Disease: A Bibliometric Landscape of Global Research Trends and Evolution 2026-05-22
  3. Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy 2026-02-24

Studies

3 studies carry this tag.

Date range

2026

Top journals

  • Aging and disease 1
  • Current neuropharmacology 1
  • Pathology, research and practice 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Optimizing Antibody-Based Therapies for Alzheimer's Disease: From Clinical Limitations to Molecular Engineering Innovations

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Aging and disease 2026-06-04 Treatments

    Antibody-based immunotherapy represents one of the most promising disease-modifying strategies for Alzheimer's disease (AD).

  2. Immunotherapeutic Innovations in Alzheimer's Disease: A Bibliometric Landscape of Global Research Trends and Evolution

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Current neuropharmacology 2026-05-22 Treatments

    Immunotherapy demonstrates disease-modifying potential in early-stage AD; however, it requires carefully optimized dosing regimens, precise biomarker-guided patient stratification, and integrated combinatorial strategies targeting Aβ, tau, and neuroinflammation.

  3. Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pathology, research and practice 2026-02-24 Treatments

    Antibody-based nanoparticles represent promising but still evolving platform for precision diagnostics and targeted therapy in AD.

All topic tags with their study counts